EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

PHARMESIS INTERNATIONAL LTD. (BFK) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of PHARMESIS INTERNATIONAL LTD. S$0.22, price S$0.10, upside +131.6%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · SG

PI Thin data Sep 28, 2026

PHARMESIS INTERNATIONAL LTD.

BFK · SG

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value 0.2200 SGD · Strongly undervalued (+131.6%)
!Quality 37/100
!Weak Growth (revenue 5y −1.5 %/yr)
!Loss-making · -9.8% net margin (TTM)
✓generates free cash flow
!Trails peers (1/8)
!Narrow moat 0/100
!Evidence only low, so the estimate is less certain
Watch PHARMESIS INTERNATIONAL LTD. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.6360 SGD 0.0753 SGD Fair Value 0.2200 SGD Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.

How to read this chart

60‑month range 0.0753 SGD – 0.6360 SGD · fair‑value band 0.1700 SGD – 0.3000 SGD · the 0.0950 SGD price screens below the 0.2200 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 28, 2026.

Follow PHARMESIS INTERNATIONAL in your weekly email

Every Wednesday you see whether PHARMESIS INTERNATIONAL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China.

Show more

Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China. The company operates through three segments: Western drugs/TCH Procurement, TCM formulated drugs/IP Rental, and Distribution. It provides prescribed products and over-the-counter drugs. The company offers Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for rheumatoid arthritis and other rheumatic diseases treatment. It also provides Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice and clear heat toxin; Shulinghou for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Fu Yang for the treatment skin pruritus and urticaria; and Xiong Dan Chuan Bei for the treatment of phlegm and cough. Further, the company distributes chemical drugs, biological raw products, TCM products, antibiotics, and antibiotic agents. The company provides western medicine products under the Kinna brand name; and TCM formulated products under the Longlife brand name. Pharmesis International Ltd. was founded in 1996 and is based in Singapore.

Stock analysis

PHARMESIS INTERNATIONAL LTD. (BFK) currently trades at 0.0950 SGD, while our model-based Fair Value estimate is 0.2200 SGD, implying the stock looks roughly 56.8% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 0.2200 SGD per share, and 7 of the 7 models we run sit above the 0.0950 SGD price.

Bear case: the Multiples group reads lowest at 0.2100 SGD, and 0 of the 7 models stay below the price. Evidence for this calculation is low.

Scenario range: 0.1700 SGD (bear) to 0.3000 SGD (bull), the price of 0.0950 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

PHARMESIS INTERNATIONAL LTD. reported revenue of 43.8M CNY in FY2025 versus 52.8M CNY in FY2021, a compound −4.6%/yr. Reported net income was −4.3M CNY in FY2025.

Key figures

Market cap 13.2M SGD (≈ $10.3M) · P/S ratio 0.30 · EPS (TTM) −0.0300 SGD · Net margin −9.8% · Return on equity −7.4% · Return on assets (EBIT) −1.6% · Operating margin −25.8% · Revenue (TTM) 43.8M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 78% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 132%, BFK screens cheaper than that median.

Fair Value models

Bear 0.1700 SGD Fair Value 0.2200 SGD Bull 0.3000 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 0.1900 SGD 0.2500 SGD 0.3500 SGD 79
Growth DCF 0.1900 SGD 0.2500 SGD 0.3400 SGD 77
5Y Revenue Exit 0.1600 SGD 0.2200 SGD 0.3000 SGD 71
All 7 models by family
DCF Models
FCF DCF 0.1900 SGD 0.2500 SGD 0.3500 SGD 79
5Y Revenue Exit 0.1600 SGD 0.2200 SGD 0.3000 SGD 71
10Y Revenue Exit 0.1700 SGD 0.2100 SGD 0.2500 SGD 66
Multiples
EV/Revenue 0.1500 SGD 0.2100 SGD 0.2700 SGD 51
Asset-Based
NCAV (Graham) 0.1700 SGD 0.2200 SGD 0.3300 SGD 51
Growth DCF
Growth DCF 0.1900 SGD 0.2500 SGD 0.3400 SGD 77
Rev-Margin DCF 0.1600 SGD 0.2200 SGD 0.3000 SGD 71

Open the full fair value analysis →

Notify me when BFK reaches fair value

Put BFK on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 41 · Market factors (momentum, volatility) 15

Profitability 12
Margins and returns on capital today
Quality Growth 11
Are margins and returns improving?
Cashflow 52
Earnings quality: real cash, not paper profit
Fin. Strength 47
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 19/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−35.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
Start year 2020 (pandemic). Over 10 years: −3.5% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.5% (2020) → −12.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−11.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −12.4% a year for the price.

Watch BFK, get fair value alerts →

Compare PHARMESIS INTERNATIONAL LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 569 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside +131.6% · Top 25%
Profitability
Return on assets −3.1% · Bottom 25%
Net margin (TTM) −9.8% · Bottom 25%
Operating margin (TTM) −25.8% · Bottom 25%
Growth and dividend
Revenue growth −62.2% · Bottom 25%
Dividend yield (TTM) 0.0% · Bottom 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 14
FUTURE (revenue growth)0 · sector 26
PAST (return on equity)0 · sector 29
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PHARMESIS INTERNATIONAL LTD. · Fair Value
0.2200 SGD +57%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "PHARMESIS INTERNATIONAL LTD. Fair Value". https://www.fairvalue-calculator.com/stock/BFK

Frequently asked questions

Is PHARMESIS INTERNATIONAL LTD. (BFK) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of 0.2200 SGD versus a price of 0.0950 SGD, about +132% upside (undervalued).
What is the fair value of BFK?
Our model-based fair value for PHARMESIS INTERNATIONAL LTD. is 0.2200 SGD (as of Sep 28, 2026), built from audited fundamentals. The current price: 0.0950 SGD.
What is the quality score of BFK?
PHARMESIS INTERNATIONAL LTD. has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PHARMESIS INTERNATIONAL LTD. (BFK)?
Our model-based price target is the fair value of 0.2200 SGD (as of Sep 28, 2026) from 7 valuation models. Cautious scenario 0.1700 SGD, optimistic scenario 0.3000 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the PHARMESIS INTERNATIONAL LTD. stock forecast for 2026?
Our models put fair value at 0.2200 SGD, about +132% upside versus a price of 0.0950 SGD (undervalued). Cautious scenario 0.1700 SGD, optimistic scenario 0.3000 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of PHARMESIS INTERNATIONAL LTD. (BFK)?
PHARMESIS INTERNATIONAL LTD. reported trailing-twelve-month revenue of about 43.8M CNY (latest available figure, as of Sep 28, 2026).
What growth is priced into PHARMESIS INTERNATIONAL LTD. (BFK)?
For today's price to be fair in a discounted-cash-flow model, PHARMESIS INTERNATIONAL LTD. would have to grow free cash flow by -11.0 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.5 % per year. As of Sep 28, 2026.
What discount rate (WACC) does the fair value of BFK use?
Our models discount PHARMESIS INTERNATIONAL LTD. at 9.5 %: a base by market capitalisation (nano), country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PHARMESIS INTERNATIONAL LTD. that is -11.0 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has PHARMESIS INTERNATIONAL LTD. (BFK) delivered so far?
Over the past 5 years revenue at PHARMESIS INTERNATIONAL LTD. grew -1.5 % a year. The price currently implies -11.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PHARMESIS INTERNATIONAL LTD. (BFK) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into PHARMESIS INTERNATIONAL LTD. (-11.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PHARMESIS INTERNATIONAL LTD. (BFK)?
The free-cash-flow yield on the price is 15.01 %: that much free cash flow PHARMESIS INTERNATIONAL LTD. produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PHARMESIS INTERNATIONAL LTD. (BFK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PHARMESIS INTERNATIONAL LTD. it is 0.2200 SGD per share (as of Sep 28, 2026), against a price of 0.0950 SGD. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is PHARMESIS INTERNATIONAL LTD. stock overvalued or undervalued in 2026?
As of Sep 28, 2026, BFK trades below its calculated fair value: price 0.0950 SGD, fair value 0.2200 SGD, a gap of about +132% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BFK?
No. The price is what the market pays today (0.0950 SGD); the fair value is what the company's own numbers justify (0.2200 SGD). For PHARMESIS INTERNATIONAL LTD. the two are 0.1250 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is PHARMESIS INTERNATIONAL LTD. worth?
The market values PHARMESIS INTERNATIONAL LTD. at about 13.2M SGD (market capitalisation, as of Sep 28, 2026). Per share that is 0.0950 SGD; our models calculate a fair value of 0.2200 SGD per share.
What do the bullish and bearish scenarios say about BFK?
Our models span a range for PHARMESIS INTERNATIONAL LTD.: cautious scenario 0.1700 SGD, base 0.2200 SGD, optimistic 0.3000 SGD per share (as of Sep 28, 2026, price 0.0950 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PHARMESIS INTERNATIONAL LTD. (BFK)?
Balance-sheet figures for PHARMESIS INTERNATIONAL LTD. (as of Sep 28, 2026): return on equity −7.4%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is BFK from its 52-week high?
PHARMESIS INTERNATIONAL LTD. trades at 0.0950 SGD, about 78% below its 52-week high of 0.4350 SGD and 23% above the low of 0.0770 SGD (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2200 SGD is for.
Which stocks are comparable to PHARMESIS INTERNATIONAL LTD.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PHARMESIS INTERNATIONAL LTD. stock attractive at the current price?
The data as of Sep 28, 2026: price 0.0950 SGD, calculated fair value 0.2200 SGD (+132%), Quality Score 37/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BFK calculated?
We run PHARMESIS INTERNATIONAL LTD. through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.2200 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. PHARMESIS INTERNATIONAL LTD. currently trades 57 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PHARMESIS INTERNATIONAL LTD. (BFK)?
The closing price on Sep 30, 2026 was 0.0950 SGD. Our model-based fair value is 0.2200 SGD, about +132% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PHARMESIS INTERNATIONAL LTD. right now?
The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (0.1700 SGD). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of PHARMESIS INTERNATIONAL LTD.

How large is the market capitalisation of PHARMESIS INTERNATIONAL LTD. (BFK)?
The market capitalisation of PHARMESIS INTERNATIONAL LTD. is 13.2M SGD (≈ $10.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PHARMESIS INTERNATIONAL LTD. (BFK)?
The price-to-sales ratio of PHARMESIS INTERNATIONAL LTD. is 0.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PHARMESIS INTERNATIONAL LTD. (BFK)?
Earnings per share at PHARMESIS INTERNATIONAL LTD. are −0.0300 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of PHARMESIS INTERNATIONAL LTD. (BFK)?
The net margin of PHARMESIS INTERNATIONAL LTD. is −9.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PHARMESIS INTERNATIONAL LTD. (BFK)?
The return on equity (ROE) of PHARMESIS INTERNATIONAL LTD. is −7.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PHARMESIS INTERNATIONAL LTD. (BFK)?
On an EBIT basis the return on assets of PHARMESIS INTERNATIONAL LTD. is −1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PHARMESIS INTERNATIONAL LTD. (BFK)?
The operating margin of PHARMESIS INTERNATIONAL LTD. is −25.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PHARMESIS INTERNATIONAL LTD. (BFK)?
Revenue at PHARMESIS INTERNATIONAL LTD. is growing −62.2% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does PHARMESIS INTERNATIONAL LTD. (BFK) carry?
The net debt of PHARMESIS INTERNATIONAL LTD. is 10.7M CNY (fiscal year 2025, ≈ 4.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch PHARMESIS INTERNATIONAL LTD. in the live analysis

One click puts PHARMESIS INTERNATIONAL LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.